The global medication-assisted treatment (MAT) market is projected to register a substantial CAGR of 9.4% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2019, the base year of calculation is 2021, and the forecast period is 2022 to 2029.
Market Segmentation:
Global Medication-Assisted Treatment (MAT) Market, By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram, and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral, and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals, Specialty Centres, Homecare, and Others) Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy, and Others), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Norway, Poland, Hungary, Lithuania, Austria, Ireland and Rest of Europe, China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel, Kuwait and Rest of Middle East and Africa U.S., Canada, and Mexico and Rest of North America) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of global medication-assisted treatment (MAT) are:
High prevalence of opioid use disorder and alcohol use disorder
Increasing awareness of MAT
Market Players:
Some of the major players operating in the global medication-assisted treatment (MAT) market are:
Indivior PLC
Orexo US Inc (a subsidiary of Orexo AB)
Recovery Centers of America
Alkermes
Sun Pharmaceutical Industries Ltd.
Purdue Pharma L.P.
Taj Pharmaceuticals Limited
Lannett
Hikma Pharmaceuticals PLC
Pfizer Inc.
Pinnacle Treatment Center
American Addiction Centers
Adamis Pharmaceuticals Corporation
Glenmark Pharmaceutical Inc.
Viatris Inc.
Mallinckrodt
Alvogen
Accord Healthcare
VistaPharm, Inc.
Teva Pharmaceutical Industries Ltd.
Dr. Reddy's Laboratories Ltd.
Amneal Pharmaceuticals LLC.
Titan Pharmaceuticals, Inc.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 OBJECTIVES OF THE STUDY
- 1.2 MARKET DEFINITION
- 1.3 OVERVIEW OF GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET
- 1.4 CURRENCY AND PRICING
- 1.5 LIMITATIONS
- 1.6 MARKETS COVERED
2 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SEGMENTATION
- 2.1 MARKETS COVERED
- 2.2 GEOGRAPHICAL SCOPE
- 2.3 YEARS CONSIDERED FOR THE STUDY
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
- 2.6 MULTIVARIATE MODELLING
- 2.7 PRODUCT SEGMENT LIFELINE CURVE
- 2.8 DBMR MARKET POSITION GRID
- 2.9 VENDOR SHARE ANALYSIS
- 2.10 MARKET END USER COVERAGE GRID
- 2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 EPIDEMIOLOGY
- 4.2 PESTEL
- 4.3 PORTER'S FIVE FORCES MODEL
- 4.4 ANNUAL INCIDENCE OF SUBJECTS ENTERING MEDICATION-ASSISTED TREATMENT IN ALCOHOL, OPIOID USE DISORDER, AND OPIOID OVERDOSE PREVENTION (2021)
- 4.5 ANNUAL NUMBER OF TREATMENTS WITH CLONIDINE AND WITH LOFEXIDINE IN OPIOID USE DISORDER AND OPIOID OVERDOSE PREVENTION (2021)
- 4.6 ANNUAL INCIDENCE OF INDIVIDUALS RE-ENTERING MEDICATION-ASSISTED TREATMENT. FOR EXAMPLE, SOMEONE MAY DROP OUT OF TREATMENT AND RESTART TREATMENT LATER (2021)
- 4.7 ANNUAL USE OF NALTREXONE INJECTION AS PART OF TREATMENT FOR THE INITIAL WITHDRAWAL FROM OPIOIDS, AND ANNUAL MAINTENANCE THERAPY USING NALTREXONE INJECTION (2021)
- 4.8 PIPELINE ANALYSIS FOR MEDICATION-ASSISTED TREATMENT (MAT) MARKET
5 GLOBAL MEDICATION-ASSISTED TREATMENT MARKET: REGULATIONS
6 MARKET OVERVIEW
- 6.1 DRIVERS
- 6.1.1 THE RISE IN INCIDENCE OF ALCOHOL USE DISORDER AND OPIOID USE DISORDERS
- 6.1.2 THE FUNDING BY THE GOVERNMENT FOR MEDICATION-ASSISTED TREATMENT (MAT)
- 6.1.3 THE RISE IN THE POPULATION RECEIVING MEDICATION-ASSISTED TREATMENT (MAT) AND MEDICATION-ASSISTED AWARENESS PROGRAMMESMEDICATION-ASSISTED TREATMENT (MAT)
- 6.1.4 USE OF REIMBURSEMENT FOR MEDICATION-ASSISTED TREATMENT (MAT)
- 6.2 RESTRAINTS
- 6.2.1 SIDE EFFECTS OF DRUGS USED IN MEDICATION-ASSISTED TREATMENT (MAT)
- 6.2.2 ETHICAL ISSUES RELATED TO USE OF MEDICATION-ASSISTED TREATMENTMEDICATION-ASSISTED TREATMENT (MAT)
- 6.2.3 RISE IN PRODUCT RECALLS
- 6.3 OPPORTUNITIES
- 6.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
- 6.3.2 RISE IN HEALTHCARE EXPENDITURE
- 6.4 CHALLENGES
- 6.4.1 THE LACK OF SKILLED PROFESSIONALS, REQUIRED FOR MEDICATION-ASSISTED TREATMENT
- 6.4.2 STRINGENT REGULATIONS
- 6.4.3 DISCONTINUATION OF MEDICATION-ASSISTED TREATMENT (MAT)
7 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE
- 7.1 OVERVIEW
- 7.2 MEDICATION
- 7.2.1 OPIOID DEPENDENCY MEDICATION
- 7.2.1.1 BUPRENORPHINE AND NALOXONE
- 7.2.1.2 BUPRENORPHINE
- 7.2.1.3 METHADONE
- 7.2.1.4 NALTREXONE
- 7.2.2 ALCOHOL USE DISORDER MEDICATIONS
- 7.2.2.1 NALTREXONE
- 7.2.2.2 DISULFIRAM
- 7.2.2.3 ACAMPROSATE
- 7.2.3 OPIOID OVERDOSE PREVENTION MEDICATION
- 7.3 THERAPY
- 7.3.1 BEHAVIORAL THERAPY
- 7.3.2 EDUCATIONAL THERAPY
- 7.3.3 COUNSELLING
- 7.3.4 VOCATIONAL THERAPY
- 7.3.5 OTHERS
8 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS
- 8.1 OVERVIEW
- 8.2 BUPRENORPHINE AND NALOXONE
- 8.3 NALTREXONE
- 8.4 BUPRENORPHINE
- 8.5 METHADONE
- 8.6 NALOXONE
- 8.7 DISULFIRAM
- 8.8 ACAMPROSATE
9 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE
- 9.1 OVERVIEW
- 9.2 GENERICS
- 9.3 BRANDED
- 9.3.1 SUBOXONE
- 9.3.2 VIVITROL
- 9.3.3 BUTRANS
- 9.3.4 ZUBSOLV
- 9.3.5 PROBUPHINE
- 9.3.6 OTHERS
10 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM
- 10.1 OVERVIEW
- 10.2 IMMEDIATE RELEASE
- 10.3 EXTENDED RELEASE
11 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION
- 11.1 OVERVIEW
- 11.2 ORAL
- 11.2.1 TABLET
- 11.2.2 SUBLINGUAL FILM
- 11.2.3 OTHERS
- 11.3 PARENTERAL
- 11.3.1 SOLUTION
- 11.3.2 SUSPENSION
- 11.4 OTHERS
12 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE
- 12.1 OVERVIEW
- 12.2 ADULTS
- 12.3 TEENAGE
13 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER
- 13.1 OVERVIEW
- 13.2 REHABILITATION CLINICS
- 13.3 HOSPITALS
- 13.4 SPECIALTY CENTERS
- 13.5 HOMECARE
- 13.6 OTHERS
14 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL
- 14.1 OVERVIEW
- 14.2 HOSPITAL PHARMACY
- 14.3 DIRECT TENDER
- 14.4 RETAIL PHARMACY
- 14.5 ONLINE PHARMACY
- 14.6 OTHERS
15 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION
- 15.1 OVERVIEW
- 15.2 NORTH AMERICA
- 15.2.1 U.S.
- 15.2.2 CANADA
- 15.2.3 MEXICO
- 15.3 EUROPE
- 15.3.1 GERMANY
- 15.3.2 FRANCE
- 15.3.3 U.K.
- 15.3.4 ITALY
- 15.3.5 RUSSIA
- 15.3.6 SPAIN
- 15.3.7 NETHERLANDS
- 15.3.8 SWITZERLAND
- 15.3.9 NORWAY
- 15.3.10 POLAND
- 15.3.11 HUNGARY
- 15.3.12 LITHUANIA
- 15.3.13 AUSTRIA
- 15.3.14 IRELAND
- 15.3.15 TURKEY
- 15.3.16 REST OF EUROPE
- 15.4 ASIA-PACIFIC
- 15.4.1 CHINA
- 15.4.2 JAPAN
- 15.4.3 INDIA
- 15.4.4 AUSTRALIA
- 15.4.5 SOUTH KOREA
- 15.4.6 SINGAPORE
- 15.4.7 MALAYSIA
- 15.4.8 THAILAND
- 15.4.9 INDONESIA
- 15.4.10 PHILIPPINES
- 15.4.11 VIETNAM
- 15.4.12 REST OF ASIA-PACIFIC
- 15.5 SOUTH AMERICA
- 15.5.1 BRAZIL
- 15.5.2 ARGENTINA
- 15.5.3 PERU
- 15.5.4 REST OF SOUTH AMERICA
- 15.6 MIDDLE EAST AND AFRICA
- 15.6.1 SOUTH AFRICA
- 15.6.2 SAUDI ARABIA
- 15.6.3 U.A.E
- 15.6.4 ISRAEL
- 15.6.5 EGYPT
- 15.6.6 KUWAIT
- 15.6.7 REST OF MIDDLE EAST AND AFRICA
16 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY LANDSCAPE
- 16.1 COMPANY SHARE ANALYSIS: GLOBAL
- 16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
- 16.3 COMPANY SHARE ANALYSIS: EUROPE
- 16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17 SWOT ANALYSIS
18 COMPANY PROFILE
- 18.1 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2021)
- 18.1.1 COMPANY SNAPSHOT
- 18.1.2 REVENUE ANALYSIS
- 18.1.3 COMPANY SHARE ANALYSIS
- 18.1.4 PRODUCT PORTFOLIO
- 18.1.5 RECENT DEVELOPMENTS
- 18.2 INDIVOR PLC (2021)
- 18.2.1 COMPANY SNAPSHOT
- 18.2.2 REVENUE ANALYSIS
- 18.2.3 COMPANY SHARE ANALYSIS
- 18.2.4 PRODUCT PORTFOLIO
- 18.2.5 RECENT DEVELOPMENTS
- 18.3 VIATRIS INC (2021)
- 18.3.1 COMPANY SNAPSHOT
- 18.3.2 REVENUE ANALYSIS
- 18.3.3 COMPANY SHARE ANALYSIS
- 18.3.4 PRODUCT PORTFOLIO
- 18.3.5 RECENT DEVELOPMENTS
- 18.4 SUN PHARMACEUTICAL INDUSTRIES LTD (2021)
- 18.4.1 COMPANY SNAPSHOT
- 18.4.2 REVENUE ANALYSIS
- 18.4.3 COMPANY SHARE ANALYSIS
- 18.4.4 PRODUCT PORTFOLIO
- 18.4.5 RECENT DEVELOPMENTS
- 18.5 ALKERMES (2021)
- 18.5.1 COMPANY SNAPSHOT
- 18.5.2 REVENUE ANALYSIS
- 18.5.3 COMPANY SHARE ANALYSIS
- 18.5.4 PRODUCT PORTFOLIO
- 18.5.5 RECENT DEVELOPMENTS
- 18.6 PURDUE PHARMA L.P. (2021)
- 18.6.1 COMPANY SNAPSHOT
- 18.6.2 PRODUCT PORTFOLIO
- 18.6.3 RECENT DEVELOPMENTS
- 18.7 PFIZER (2021)
- 18.7.1 COMPANY SNAPSHOT
- 18.7.2 REVENUE ANALYSIS
- 18.7.3 PRODUCT PORTFOLIO
- 18.7.4 RECENT DEVELOPMENTS
- 18.8 GLENMARK PHARMACEUTICAL INC (2021)
- 18.8.1 COMPANY SNAPSHOT
- 18.8.2 REVENUE ANALYSIS
- 18.8.3 PRODUCT PORTFOLIO
- 18.8.4 RECENT DEVELOPMENTS
- 18.9 DR. REDDY'S LABORATORIES LTD (2021)
- 18.9.1 COMPANY SNAPSHOT
- 18.9.2 REVENUE ANALYSIS
- 18.9.3 PRODUCT PORTFOLIO
- 18.9.4 RECENT DEVELOPMENTS
- 18.10 ALVOGEN (2021)
- 18.10.1 COMPANY SNAPSHOT
- 18.10.2 PRODUCT PORTFOLIO
- 18.10.3 RECENT DEVELOPMENTS
- 18.11 ADAMIS PHARMACEUTICALS CORPORATION (2021)
- 18.11.1 COMPANY SNAPSHOT
- 18.11.2 REVENUE ANALYSIS
- 18.11.3 PRODUCT PORTFOLIO
- 18.11.4 RECENT DEVELOPMENTS
- 18.12 ACCORD HEALTHCARE (A SUBSIDIARY OF INTAS PHARMACEUTICALS)
- 18.12.1 COMPANY SNAPSHOT
- 18.12.2 PRODUCT PORTFOLIO
- 18.12.3 RECENT DEVELOPMENTS
- 18.13 AMNEAL PHARMACEUTICALS LLC (2021)
- 18.13.1 COMPANY SNAPSHOT
- 18.13.2 REVENUE ANALYSIS
- 18.13.3 PRODUCT PORTFOLIO
- 18.13.4 RECENT DEVELOPMENTS
- 18.14 AMERICAN ADDICTION CENTERS (2021)
- 18.14.1 COMPANY SNAPSHOT
- 18.14.2 PRODUCT PORTFOLIO
- 18.14.3 RECENT DEVELOPMENTS
- 18.15 HIKMA PHARMACEUTICALS PLC (2021)
- 18.15.1 COMPANY SNAPSHOT
- 18.15.2 REVENUE ANALYSIS
- 18.15.3 PRODUCT PORTFOLIO
- 18.15.4 RECENT DEVELOPMENTS
- 18.16 LANNETT (2021)
- 18.16.1 COMPANY SNAPSHOT
- 18.16.2 REVENUE ANALYSIS
- 18.16.3 PRODUCT PORTFOLIO
- 18.16.4 RECENT DEVELOPMENT
- 18.17 MALLINCKRODT (2021)
- 18.17.1 COMPANY SNAPSHOT
- 18.17.2 REVENUE ANALYSIS
- 18.17.3 PRODUCT PORTFOLIO
- 18.17.4 RECENT DEVELOPMENT
- 18.18 OREXO US INC (A SUBSIDIARY OF OREXO, INC) (2021)
- 18.18.1 COMPANY SNAPSHOT
- 18.18.2 REVENUE ANALYSIS
- 18.18.3 PRODUCT PORTFOLIO
- 18.18.4 RECENT DEVELOPMENT
- 18.19 PINNACLE TREATMENT CENTERS
- 18.19.1 COMPANY SNAPSHOT
- 18.19.2 PRODUCT PORTFOLIO
- 18.19.3 RECENT DEVELOPMENT
- 18.20 RECOVERY CENTERS OF AMERICA
- 18.20.1 COMPANY SNAPSHOT
- 18.20.2 PRODUCT PORTFOLIO
- 18.20.3 RECENT DEVELOPMENTS
- 18.21 TAJ PHARMACEUTICALS LIMITED
- 18.21.1 COMPANY SNAPSHOT
- 18.21.2 PRODUCT PORTFOLIO
- 18.21.3 RECENT DEVELOPMENTS
- 18.22 TITAN PHARMACEUTICALS (2021)
- 18.22.1 COMPANY SNAPSHOT
- 18.22.2 REVENUE ANALYSIS
- 18.22.3 PRODUCT PORTFOLIO
- 18.22.4 RECENT DEVELOPMENTS
- 18.23 VISTAPHARM, INC (A SUBSIDIARY OF VERTICE PHARMA, LLC. (2021))
- 18.23.1 COMPANY SNAPSHOT
- 18.23.2 PRODUCT PORTFOLIO
- 18.23.3 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS